Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
about
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosisInhaled antibiotics for pulmonary exacerbations in cystic fibrosisInhaled antibiotics for long-term therapy in cystic fibrosisNebulised anti-pseudomonal antibiotics for cystic fibrosisDigitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cellsInfection control and the significance of sputum and other respiratory secretions from adult patients with cystic fibrosisCharacteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patientTobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic Pseudomonas Aeruginosa Infection in Cystic FibrosisStenotrophomonas maltophilia: an emerging global opportunistic pathogenClinical applications of pulmonary delivery of antibioticsCandida albicans Inhibits Pseudomonas aeruginosa Virulence through Suppression of Pyochelin and Pyoverdine BiosynthesisPseudomonas aeruginosa biofilms in cystic fibrosisInhaled Antibiotics for Gram-Negative Respiratory InfectionsRegulation of membrane permeability by a two-component regulatory system in Pseudomonas aeruginosaEarly anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'Exacerbations in cystic fibrosis: 2 . prevention.Nutrient availability as a mechanism for selection of antibiotic tolerant Pseudomonas aeruginosa within the CF airway.Inhaled antibiotics for lower airway infections.Trichosporon mycotoxinivorans infection in patients with cystic fibrosisInhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection.Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial.Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCRActivities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis.Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips.The role of Pseudomonas lipopolysaccharide in cystic fibrosis airway infectionInterspecies competition triggers virulence and mutability in Candida albicans-Pseudomonas aeruginosa mixed biofilms.Emergence of Pseudomonas aeruginosa strains producing high levels of persister cells in patients with cystic fibrosis.Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells.Characterization and quantification of the fungal microbiome in serial samples from individuals with cystic fibrosisThe rationale for aerosolized antibiotics.Trichosporon mycotoxinivorans, a novel respiratory pathogen in patients with cystic fibrosisAntimicrobial susceptibility and synergy studies of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis.Laboratory aspects of management of chronic pulmonary infections in patients with cystic fibrosis.Infection control in cystic fibrosis.Antibiotic treatment of multidrug-resistant organisms in cystic fibrosis.Nosocomial pneumonia in the intensive care unit: controversies and dilemmas.Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study.Inhaled therapeutics for prevention and treatment of pneumoniaNebulized antibiotic therapy: the evidence.
P2860
Q24188054-A01C50E2-34AD-463D-B5CB-02A40DFD3BF3Q24202283-376E15AD-9A95-4306-ADAE-CE7FA0DF38C3Q24235635-B9BB7166-8A24-436C-A086-44DD32124C8CQ24247996-EAB07729-36E3-47B1-84D4-A7996A0C27F8Q24562089-A8151AF3-9953-434A-9D2D-999075BB77C1Q24792662-FC07C414-6660-4244-8104-6E775A8E4BBFQ26752680-217A5767-F132-4A0C-B7E9-B3E6D4F11588Q26829604-843F2AC9-B793-4DAF-B957-0F600F15567CQ26995336-A18161F4-99CD-49E8-AF69-DF2D54804C2AQ26996053-C800BC85-2BFC-464A-B010-42ABAFF3DFF1Q27317563-7A4845FF-4770-4038-A3EE-2DB06C32B3F4Q28299966-8BC283A8-C936-487E-A881-976CA3138A68Q28386160-EA0DEF9A-28F6-4FE1-918C-1157D8C4BEC5Q28492587-C44BD739-F8E0-419E-916B-3EBDD8F70940Q30436229-22756E91-6F01-4D35-853E-43E772549997Q30480308-2AAF237C-1D49-4A44-9490-46B439FA3BD8Q33523793-D96B2890-2B9E-44A4-A6B5-CBE88CEE4571Q33640488-0C45F319-B186-485A-B77B-66471E9358DBQ33703666-7D5AB15C-A884-43FD-A9C8-36DA94692E5AQ33901651-7EACC6BF-3A2F-4865-862E-3B748F8B4DF0Q33946709-0DBDEBA2-BC45-4833-9964-EC623E495D13Q33957168-670F50CC-B5F0-4B7A-80F3-A199440AC6C7Q33970448-D69671B3-F78D-446B-BC93-34B88CE71878Q33978230-3E8774CB-089F-45D5-9002-01169CD0CE17Q34042263-8372E451-346F-47F9-B196-CA0E1B164BF2Q34105561-0B85C34A-FF85-4B6F-882E-612163856653Q34284493-DA6DE873-FE83-493E-AF31-757407827BF1Q34309282-E97C07B9-3ABD-49C2-9663-1A441E7E539DQ34478025-4A7F533E-1AD7-499C-A0CA-7A5C03B30932Q34536205-5A8DC9FE-1962-4FBE-AD13-238FD6072450Q34566912-66C4B57E-0871-44C8-A1E4-11866F5E87F5Q34995831-1CAFD1E6-B204-47A3-92A7-C22F485BC34CQ35005445-7F744EF9-F87A-4641-ACCA-2DC3B17E0B0AQ35213050-E895FCA1-3369-4E1A-9FEE-0EA1E26507B2Q35545544-DB812FFA-0DA9-43A0-AD84-2F1D8B3EDED0Q35627661-BA9A4079-384A-48B6-9C35-3D2BEEFDCDCCQ35702259-9E647D2D-8E2D-4947-9465-44CA985EEAFDQ35922887-147358CE-215B-4B49-94C5-1E389E6E071AQ35925366-2F28EC23-130F-48A5-857D-6C5424FE688EQ36310044-CF0653C1-EABC-4274-8C68-E805FD18E052
P2860
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Effect of chronic intermittent ...... patients with cystic fibrosis.
@en
Effect of chronic intermittent ...... patients with cystic fibrosis.
@nl
type
label
Effect of chronic intermittent ...... patients with cystic fibrosis.
@en
Effect of chronic intermittent ...... patients with cystic fibrosis.
@nl
prefLabel
Effect of chronic intermittent ...... patients with cystic fibrosis.
@en
Effect of chronic intermittent ...... patients with cystic fibrosis.
@nl
P2093
P356
P1476
Effect of chronic intermittent ...... patients with cystic fibrosis.
@en
P2093
Montgomery AB
Van Dalfsen JM
P304
P356
10.1086/314727
P407
P577
1999-05-01T00:00:00Z